Cargando…

Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles

Cyclosporine A (CsA) is an immunosuppressant frequently used in the therapy of autoimmune disorders, including skin-related diseases. Aiming towards topical delivery, CsA was successfully incorporated into lipid nanoparticles of Lipocire DM and Pluronic F-127 using the hot homogenization method. Two...

Descripción completa

Detalles Bibliográficos
Autores principales: Essaghraoui, Abderrazzaq, Belfkira, Ahmed, Hamdaoui, Bassou, Nunes, Cláudia, Lima, Sofia A. Costa, Reis, Salette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780175/
https://www.ncbi.nlm.nih.gov/pubmed/31461853
http://dx.doi.org/10.3390/nano9091204
_version_ 1783457068065226752
author Essaghraoui, Abderrazzaq
Belfkira, Ahmed
Hamdaoui, Bassou
Nunes, Cláudia
Lima, Sofia A. Costa
Reis, Salette
author_facet Essaghraoui, Abderrazzaq
Belfkira, Ahmed
Hamdaoui, Bassou
Nunes, Cláudia
Lima, Sofia A. Costa
Reis, Salette
author_sort Essaghraoui, Abderrazzaq
collection PubMed
description Cyclosporine A (CsA) is an immunosuppressant frequently used in the therapy of autoimmune disorders, including skin-related diseases. Aiming towards topical delivery, CsA was successfully incorporated into lipid nanoparticles of Lipocire DM and Pluronic F-127 using the hot homogenization method. Two different nanocarriers were optimized: solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) where oleic acid was the liquid lipid. The developed nanoparticles showed mean sizes around 200 nm, a negative surface charge, and drug entrapment efficiencies around 85% and 70% for SLNs and NLCs, respectively. The spherical CsA-loaded lipid nanoparticles were stable for 9 weeks when stored at room temperature, and exhibited in vitro pH-dependent release under skin mimetic conditions, following the Peppas–Korsmeyer model. CsA, when loaded in SLNs, was safe to be used up to 140 μg mL(−1) in fibroblasts and keratinocytes, while CsA-loaded NLCs and free drug exhibited IC(50) values of 55 and 95 μg mL(−1) (fibroblasts) and 28 and 30 μg mL(−1) (keratinocytes), respectively. The developed SLNs were able to retain the drug in pork skin with a reduced permeation rate in relation to NLCs. These findings suggest that SLNs are a potential alternative to produce stable and safe CsA nanocarriers for topical administration.
format Online
Article
Text
id pubmed-6780175
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67801752019-10-30 Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles Essaghraoui, Abderrazzaq Belfkira, Ahmed Hamdaoui, Bassou Nunes, Cláudia Lima, Sofia A. Costa Reis, Salette Nanomaterials (Basel) Article Cyclosporine A (CsA) is an immunosuppressant frequently used in the therapy of autoimmune disorders, including skin-related diseases. Aiming towards topical delivery, CsA was successfully incorporated into lipid nanoparticles of Lipocire DM and Pluronic F-127 using the hot homogenization method. Two different nanocarriers were optimized: solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) where oleic acid was the liquid lipid. The developed nanoparticles showed mean sizes around 200 nm, a negative surface charge, and drug entrapment efficiencies around 85% and 70% for SLNs and NLCs, respectively. The spherical CsA-loaded lipid nanoparticles were stable for 9 weeks when stored at room temperature, and exhibited in vitro pH-dependent release under skin mimetic conditions, following the Peppas–Korsmeyer model. CsA, when loaded in SLNs, was safe to be used up to 140 μg mL(−1) in fibroblasts and keratinocytes, while CsA-loaded NLCs and free drug exhibited IC(50) values of 55 and 95 μg mL(−1) (fibroblasts) and 28 and 30 μg mL(−1) (keratinocytes), respectively. The developed SLNs were able to retain the drug in pork skin with a reduced permeation rate in relation to NLCs. These findings suggest that SLNs are a potential alternative to produce stable and safe CsA nanocarriers for topical administration. MDPI 2019-08-27 /pmc/articles/PMC6780175/ /pubmed/31461853 http://dx.doi.org/10.3390/nano9091204 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Essaghraoui, Abderrazzaq
Belfkira, Ahmed
Hamdaoui, Bassou
Nunes, Cláudia
Lima, Sofia A. Costa
Reis, Salette
Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles
title Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles
title_full Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles
title_fullStr Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles
title_full_unstemmed Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles
title_short Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles
title_sort improved dermal delivery of cyclosporine a loaded in solid lipid nanoparticles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780175/
https://www.ncbi.nlm.nih.gov/pubmed/31461853
http://dx.doi.org/10.3390/nano9091204
work_keys_str_mv AT essaghraouiabderrazzaq improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles
AT belfkiraahmed improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles
AT hamdaouibassou improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles
AT nunesclaudia improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles
AT limasofiaacosta improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles
AT reissalette improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles